If Cannabis Is Reclassified, What Will Happen to the Marketplace? – Diagnosing Health Care
Podcast - DEA Plants the Seed for Rescheduling Marijuana: What's Next?
The Presumption of Innocence Podcast: Special Edition | Episode 36 - Rolling Change: The DEA Turns Over a New Leaf on Marijuana Scheduling
A history of the decline and rise of the marijuana empire
Podcast: Non-binding Guidance: FDA’s Regulation of Products Containing CBD
Eleven Republican AGs, led by Nebraska AG Mike Hilgers, submitted comments opposing the DEA’s notice of proposed rulemaking (NPRM) that would move marijuana from Schedule I to Schedule III of the Controlled Substances Act...more
The Department of Justice (DOJ) published a Notice of Proposed Rulemaking to reschedule marijuana from Schedule I to Schedule III of the federal Controlled Substances Act (CSA) in the Federal Register on May 21, 2024. If the...more
Xylazine is a non-scheduled, non-opioid sedative/analgesic medication that is widely used in veterinary medicine. Xylazine was first produced by Bayer Pharmaceuticals in 1962, but investigations for use in humans were not...more
The DEA struggles to balance the pressing need to provide pain relief for those suffering from the novel coronavirus with the ongoing effort to reduce the opioid epidemic in the United States. I. Overview on the DEA and the...more
While the legal landscape continues to evolve in the cannabis industry, making entry into the space a potentially risky proposition, the passage of the Agriculture Improvement Act of 2018 (the “Farm Bill”) can be a real game...more